Recombinant Influenza Vaccine

BIOLOGICAL3 trials

Sponsors

Protein Sciences Corporation, Marshfield Clinic Research Foundation, Insight Therapeutics, LLC

Conditions

Human InfluenzaImmune ResponseInfluenzaInfluenza -Like IllnessInfluenza, Human

Phase 4

Recombinant Influenza Vaccination in U.S. Nursing Homes

Insight Therapeutics, LLCInfluenza, Influenza, Human, Influenza -Like Illness

Start: 2019-07-20End: 2023-12-31Updated: 2023-03-15

Unknown Phase

Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults

CompletedNCT02600585

Protein Sciences CorporationHuman Influenza

Start: 2015-11-30End: 2016-09-30Updated: 2017-10-12

Open-Label Influenza Vaccine Evaluation

CompletedNCT02872311

Marshfield Clinic Research FoundationImmune Response

Start: 2016-09-30End: 2018-09-30Updated: 2025-12-10

Related Papers

Recombinant vs Egg-Based Quadrivalent Influenza Vaccination for Nursing Home Residents

JAMA Network Open2025-01-023 citations

Serologic response to sequential vaccination with enhanced influenza vaccines: Open label randomized trial among adults aged 65–74 years

Vaccine2021-11-105 citations

LB-19. Association between contract staffing and reported outbreaks of SARS-CoV-2 in a cluster-randomized trial of 965 U.S. nursing homes

Open Forum Infectious Diseases2020-10-011 citations

Clinical trial to assess immunogenicity of high-dose, adjuvanted, and recombinant influenza vaccines against cell-grown A(H3N2) viruses in adults 65 to 74 years, 2017-2018.

2020-03-0416 citations